Pfizer’s investigational vaccine candidate Bivalent rLP2086 receives US Food and Drug Administration breakthrough therapy designation for potential

21-03-2014 Business Wire HealthComments (0)

PfizerrLP2086USA

Pfizer (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pfizer’s vaccine candidate, bivalent rLP2086, currently under investigation for the prevention of invasive meningococcal disease due to Neisseria meningitidis serogroup B in persons 10 – 25 years of age. Disease caused by Neisseria meningitidis serogroup B has been estimated at between 20,000 and 80,000 cases per year globall

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top